Predictions regarding the on-going burden of SARS-CoV-2, and vaccine recommendations, require an understanding of infection-associated immune protection. We assessed whether early COVID-19 provided protection a
BMC Infectious Diseases (2024) 24:89 https://doi.org/10.1186/s12879-023-08835-3 BMC Infectious Diseases RESEARCH Open Access Clinical antiviral efficacy of favipiravir in early COVID‑19 (PLATCOV): an open‑label, randomised, controlled, adaptive platform trial Viravarn Luvira1, ...
COVID-19 is a respiratory condition caused by a coronavirus. Some people are infected but don’t notice any COVID-19 symptoms (doctors call that being asymptomatic). Most people have mild symptoms and get better on their own. But some have severe problems, such as trouble breathing. The od...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a c
First, participants were asked about 17 symptoms identified early in the trial as important symptoms of COVID-19. During the pandemic, knowledge of PCC expanded to include more neurocognitive symptoms; however, we could not conduct additional validated measurements of sleep or neurologic function as ...
seven million had died. (WHO2022) The initial reports of high infectivity before symptoms were manifest suggested that the pathogen has some unique characteristics, also evident in the unusual number of long-term complications suffered by a small but significant percentage of COVID-19-infected ...
(CDC) estimated a 2–14 day range], with the shortest being 1 day and the vast majority within 2 weeks. A proportion of infected subjects may remain asymptomatic. Fever, cough, and shortness of breath were the first typical symptoms of COVID-19 pneumonia initially highlighted by CDC, and...
We agree with the suggestion from Scotto di Vetta et al [3] that it should be required to promptly initiate a therapy at the earliest onset of symptoms to stop the progression of COVID-19. This would ultimately reduce the risk of cytokine storm, thrombosis, and, consequently, hospitalization...
This differential gene expression pattern was specific for the first week after onset of symptoms and also enabled us to discriminate between patients with fatal outcomes of COVID-19 and those who finally recovered. Moreover, we demonstrate an impaired anti-SARS-CoV2 NK cell activity, which was...
65 million people worldwide are estimated to suffer from long-term symptoms after their SARS-CoV-2 infection (Long COVID). However, there is still little information about the early recovery among those who initially developed Long COVID, i.e. had sympto